Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02492529
Other study ID # 2014-A01123-44
Secondary ID 35RC14_9777_EPMR
Status Completed
Phase N/A
First received
Last updated
Start date July 21, 2015
Est. completion date December 31, 2017

Study information

Verified date May 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Unrandomized, unblinded, monocentric comparative Functional Magnetic Resonance Imaging study.


Description:

Prospective functional Magnetic Resonance Imaging study involving a group of participants with Mild Cognitive Impairment due to AD and a control participants group matched for age, education level, verbal Intelligence Quotient as assessed through the French version of the National Adult Reading Test and income group following National Institute of Statistics and Economics Studies classification.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 31, 2017
Est. primary completion date December 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 75 Years
Eligibility Inclusion Criteria: Volunteers (pilot phase) - Aged 25 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Free from any medical or psychiatric condition that may impact cognition - Having given written informed consent Volunteers (experimental phase) - Aged 60 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Free from any medical or psychiatric condition that may impact cognition - Having given written informed consent AD-MCI participants - Aged 60 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Fulfilling criteria for " AD-MCI " (Albert et al., 2011) - Have been seen in a memory medical center or in Memory Resources and Research Medical Center for cognitive symptoms - Free from any medical or psychiatric condition that may impact cognition - Able to understand and consent - Having given written informed consent Exclusion Criteria: MRI contraindications (all participants) - Claustrophobia - Wearing of any metal implant such as: - Heart pacemaker - Iron-magnetic surgical clips - Any metallic foreign body in the eye or brain Other criteria (all participants) - Significant history of neurological or psychiatric disorders - Ongoing medication that may affect cognitive performances - Sensory deficit that may interfere with the experimental design (e.g. uncorrected visual impairment) - Lack of sufficient cooperation during the cognitive tasks - Persons under major legal protection and/or deprived of liberty Other criteria (control participants) - Global cognitive impairment attested by Mattis Dementia Rating Scale or Mini-Mental State Examination, according to available normative data Other criteria (AD-MCI participants) - 7 items modified Hachinski ischemic score > 2 (Hachinski et al., 2012) - Dementia (McKahn, et al., 2011)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Neuropsychological tests
Scales and tests to evaluate: Global cognitive performance Handedness Memory functions performance Gestural praxis functions performance Lexical and semantic functions performance Executive functions performance Memory disorders Way of life Mood
Device:
A cranial MRI

Other:
Experimental procedure


Locations

Country Name City State
France Centre Hospitalier Universitaire Rennes

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

References & Publications (1)

Jonin PY, Duche Q, Bannier E, Corouge I, Ferre JC, Belliard S, Barillot C, Barbeau EJ. Building memories on prior knowledge: behavioral and fMRI evidence of impairment in early Alzheimer's disease. Neurobiol Aging. 2022 Feb;110:1-12. doi: 10.1016/j.neurob — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group 3 months
Primary Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group 3 months
Secondary Significant group effect on the pattern of % BOLD signal change in across the brain 3 months
Secondary Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI) 3 months
Secondary Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct) 3 months
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02094729 - A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1